Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.
about
International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease statesA chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapyLiver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancySynthesis, characterization and stability of a luteinizing hormone-releasing hormone (LHRH)-functionalized poly(amidoamine) dendrimer conjugate.Research highlights: translating chips.[DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo.Molecular MRI for sensitive and specific detection of lung metastases.Peptide targeting of platinum anti-cancer drugsBioactive unnatural somatostatin analogues through bioorthogonal iodo- and ethynyl-disulfide intercalators.Identification of urushiols as the major active principle of the Siddha herbal medicine Semecarpus Lehyam: Anti-tumor agents for the treatment of breast cancerPeptide analogs in the therapy of prostate cancer.Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action.The gonadotrophin-releasing hormone receptor: signalling, cycling and desensitisation.Clinical significance of prognostic and predictive markers in colorectal cancer.Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.Targeting prostate cancer with radiolabelled bombesins.Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.Plasma membrane expression of GnRH receptors: regulation by antagonists in breast, prostate, and gonadotrope cell linesCancer treatment using peptides: current therapies and future prospectsTargeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.Design and development of molecular imaging probes.LHRH-targeted nanogels as a delivery system for cisplatin to ovarian cancer.A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancerExpression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.Receptor-mediated tumor targeting based on peptide hormones.Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.Peptide-mediated targeted drug delivery.Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer.Cancer nanomedicines targeting tumor extracellular pH.Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.Gonadotropin-releasing hormone receptor expression in endometrial stromal sarcomas: an immunohistochemical study.GnRH and GnRH receptors in the pathophysiology of the human female reproductive system.Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells.Oligonucleotide-based theranostic nanoparticles in cancer therapy.Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety.Anti-cancer effects of novel doxorubicin prodrug PDOX in MCF-7 breast cancer cells.
P2860
Q24643524-7BDCB3B1-7763-4608-BD61-63DCF9D0AB94Q30779111-BFB060D4-9100-481A-B66E-FC25E2EE2331Q33247993-39971380-3CF3-4D32-AE2D-E7A66E037AB9Q33313432-DD268D8A-98A2-4171-A759-000FEB836F4FQ33443071-4BA34C93-4222-49E1-B56B-39496870F577Q33724860-F73A88B1-0A34-44C0-8335-7C4067AFF575Q33734761-709ED2AF-3560-4A63-B09E-A5677A1F3809Q33937941-A71FDB77-617D-4082-AD21-10CDDF739983Q33958534-55967398-EEA6-46AC-9A60-85C49E733CE5Q33966511-3984371B-2F2C-412B-996D-FC2985D8D321Q34057795-CA839620-868A-4E99-82FD-53062F31CE35Q34101055-1420708E-B3FF-48EE-964A-6519938621A9Q34204370-304106F3-F721-4E2C-A094-DEEF7893FD05Q34589345-A9812C77-769D-4EA9-B9C8-9B39F6380717Q34798558-A819ED26-4B8A-40DE-8597-37A916B2EBC0Q34979199-F599280C-04DF-46A3-9BC8-90F95ACCBB41Q35199203-56AABD0C-3DF1-4A79-98FB-FDB16F79109AQ35214872-7398F52A-AF13-4666-AA13-455170639EB8Q36202016-86C080C9-7132-4B00-A75C-1749F2DA1ECBQ36436767-14B31BB8-10CB-447C-B96C-6C229FAACFDEQ36515785-6BC2580B-3FD0-48BC-A226-2A8F8537F498Q36619952-BFE7B842-DD1A-460D-9C17-7CCD486669E2Q36644341-71987CD3-0E9C-4B76-A5FB-75E8DDC86CC5Q36748502-FB684B48-03BF-4A3C-9BFC-12ADAC72CDD6Q36785137-7B969558-2A52-4E72-9D4C-98667422CFC0Q37259176-9830A369-01A6-420F-B201-C401B3ED401FQ37274382-16A658C1-9AB5-47F5-9C30-96010904A966Q37323454-38E2B5D6-FB60-45C0-B6CC-E46DDE7A226CQ37641368-2478E42B-38F4-4AA4-BA87-7F27520E95A5Q37724516-6E0FA6EE-578C-4C05-9D08-DF6B14AD248CQ37785045-14CD24EC-30F0-4480-B775-276457DD432EQ37859389-6592D8A6-1CB7-4365-9BDD-300FF101F8FDQ37955451-60DE7876-8E0A-4A3B-920E-262A1F870A2DQ38311828-8B539698-2EA9-45E2-9D8D-DDBDCEC28113Q38445338-A7CAC8D0-3D79-4622-9F64-C48B493F12B0Q38682630-94EBA44C-FDE6-4FE3-A8BD-DA3003354E98Q38756598-CEFB573A-9661-4A88-9335-B41E02455268Q38814327-019F18CD-93B3-4FC1-AB64-FBAE0B682A00Q38865705-25026E8E-804D-4A97-8AB1-1024F0D7984AQ38964767-FFF924C7-1D65-440A-9296-34A0949671B4
P2860
Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Cancer chemotherapy based on t ...... to their receptors on tumors.
@ast
Cancer chemotherapy based on t ...... to their receptors on tumors.
@en
type
label
Cancer chemotherapy based on t ...... to their receptors on tumors.
@ast
Cancer chemotherapy based on t ...... to their receptors on tumors.
@en
prefLabel
Cancer chemotherapy based on t ...... to their receptors on tumors.
@ast
Cancer chemotherapy based on t ...... to their receptors on tumors.
@en
P356
P1476
Cancer chemotherapy based on t ...... s to their receptors on tumors
@en
P2093
P356
10.1530/EJE.0.1410001
P577
1999-07-01T00:00:00Z